Marksans Pharma Limited (BOM:524404)

Market Cap	102.44B
Revenue (ttm)	24.74B
Net Income (ttm)	3.68B
Shares Out	n/a
EPS (ttm)	8.13
PE Ratio	27.81
Forward PE	n/a
Dividend	0.60 (0.26%)
Ex-Dividend Date	Sep 17, 2024

Volume	22,130
Average Volume	99,008
Open	225.00
Previous Close	227.90
Day's Range	225.00 - 235.55
52-Week Range	126.05 - 358.50
Beta	n/a
RSI	37.41
Earnings Date	Feb 11, 2025

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 1,141
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524404

Financial Performance

In 2023, Marksans Pharma's revenue was 21.77 billion, an increase of 17.56% compared to the previous year's 18.52 billion. Earnings were 3.14 billion, an increase of 17.80%.